A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2001
11/22/2001	WO2001087843A1 Compounds for treating disorders where a decreased level of plasma ffa is desired
11/22/2001	WO2001087840A1 Propanoic acid derivatives as integrin receptor antagonists
11/22/2001	WO2001087839A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001	WO2001087838A1 Cyclohexane derivatives and their use as therapeutic agents
11/22/2001	WO2001087836A1 Novel $g(b crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same
11/22/2001	WO2001087835A1 Α crystalline form of perindopril tert-butylamine salt
11/22/2001	WO2001087830A2 Substituted thioacetamides
11/22/2001	WO2001087828A1 N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
11/22/2001	WO2001087823A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives
11/22/2001	WO2001087376A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
11/22/2001	WO2001087374A1 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087373A1 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087346A2 Dendritic cells loaded with toxic substances
11/22/2001	WO2001087343A2 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	WO2001087342A2 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087341A1 Agents for preventing or ameliorating insulin resistance and/or obesity
11/22/2001	WO2001087338A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	WO2001087337A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	WO2001087336A1 Cancer treatments by using a combination of an antibody against her2 and interleukin -2
11/22/2001	WO2001087334A1 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
11/22/2001	WO2001087311A1 Immunopotentiator
11/22/2001	WO2001087308A1 Treatment of fibromyalgia and chronic fatigue syndrome
11/22/2001	WO2001087307A2 Compositions and methods for the treatment of cancer
11/22/2001	WO2001087306A2 Compositions and methods for the treatment of colorectal cancer
11/22/2001	WO2001087299A1 Aralkyl ester soft drugs
11/22/2001	WO2001087297A1 Cannabinoid drugs
11/22/2001	WO2001087296A1 Methods for decreasing cell proliferation based on (3r, 4r)δ8-tetrahydrocannabinol-11-oic acids
11/22/2001	WO2001087295A1 Methods for decreasing cell proliferation based on (3r, 4r)-δ8-tetrahydrocannabinol-11-oic acids
11/22/2001	WO2001087294A1 Phosphate transport inhibitors
11/22/2001	WO2001087293A1 -secretase inhibitors
11/22/2001	WO2001087287A2 Use of pyrazole derivatives for treating infertility
11/22/2001	WO2001087286A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
11/22/2001	WO2001087284A2 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	WO2001087272A2 Encapsulating a toxic core within a non-toxic region in an oral dosage form
11/22/2001	WO2001087267A1 Protein matrix materials, devices and methods of making and using thereof
11/22/2001	WO2001087266A1 Stabilized aqueous suspensions for parenteral use
11/22/2001	WO2001087263A2 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087238A2 Induction of apoptosis and cell growth inhibition by protein 4.33
11/22/2001	WO2001087071A1 Methods for enriching for quiescent cells in hematopoietic cell populations
11/22/2001	WO2001087039A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
11/22/2001	WO2001087038A2 β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE
11/22/2001	WO2001046128A3 Tryptase inhibitors
11/22/2001	WO2001042246A3 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
11/22/2001	WO2001041535A3 Eplerenone crystalline form
11/22/2001	WO2001041534A3 Pseudomycin phosphate prodrugs
11/22/2001	WO2001034119A3 Inhibitors of crystallization in a solid dispersion
11/22/2001	WO2001034093A3 Potentiation of prodrug efficacy
11/22/2001	WO2001032691A8 Hcv ns3 protease inhibitors
11/22/2001	WO2001030969A8 Stanniocalcin proteins and nucleic acids and methods based thereon
11/22/2001	WO2001030781A3 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
11/22/2001	WO2001030752A3 Indole compounds for treating bacterial infections
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	WO2001027255A3 Nucleic acid coding for a ctage gene family, use and production thereof
11/22/2001	WO2001027146A3 Chemokine receptor
11/22/2001	WO2001025239A3 Oxazinoquinolones useful for the treatment of viral infections
11/22/2001	WO2001018169A3 Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases
11/22/2001	WO2001017211A3 Communications system
11/22/2001	WO2001007637B1 Conditionally controlled, attenuated hiv vaccine
11/22/2001	WO2000056681A9 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction
11/22/2001	WO2000055633A9 Methods of screening for colorectal cancer modulators
11/22/2001	US20010044538 Mitogen-activated protein (MAP) kinase; treating inflammatory diseases; compounds such as 3-(4-fluorophenyl)-1-hydroxy-2-(pyridin-4-yl)-1H-pyrrolo(3,2-b)pyridine
11/22/2001	US20010044537 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine
11/22/2001	US20010044536 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
11/22/2001	US20010044535 Heterocyclic compounds containing a guanidine mimic, for inhibition of cell adhesion, treatment of angiogenesis disorders, inflammation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration
11/22/2001	US20010044474 Hydrogel-driven layered drug dosage form
11/22/2001	US20010044468 Reduced in the body to produce a benzamidine; nontoxic
11/22/2001	US20010044459 Hydroxamic acid derivatives
11/22/2001	US20010044456 Non-systemic control of parasites
11/22/2001	US20010044451 Tyrosine kinase inhibitors
11/22/2001	US20010044450 5-HT3 receptor antagonists such as alosetron to treat nonconstipated female irritable bowel syndrome
11/22/2001	US20010044442 Dimethoxy quinazolines for treating diabetes
11/22/2001	US20010044441 And female sexual dysfunction, premature labour or dysmenorrhea
11/22/2001	US20010044436 Bicyclic inhibitors of glycogen synthase kinase 3
11/22/2001	US20010044430 Cosmetic composition containing a steroid and a 2-alkylalkanol or an ester thereof
11/22/2001	US20010044428 Aminopyridines and methods of using thereof
11/22/2001	US20010044425 Therapeutically effective amount of ferrous ion and a therapeutically effective amount of an ascorbate
11/22/2001	US20010044144 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
11/22/2001	US20010044122 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
11/22/2001	US20010044120 Useful for the prevention or treatment of peptic ulcers in humans or mammals.
11/22/2001	US20010043950 Core of fluvastatin, hydroxypropyl methyl cellulose and optionally other excipients, dosage form is color-stable during storage
11/22/2001	US20010043922 Recombinants of the multiply deficient adenoviral vectors; a therapeutic method and their use particularly relating to gene therapy and vaccination
11/22/2001	US20010043921 A retroviral vector of a heterologous nucleic acid sequence as well as at least one sequence allowing site-specific integration of the sequence into a non-coding region of a genome; gene therapy of genetic defects; viricides
11/22/2001	DE10023484A1 New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
11/22/2001	CA2781858A1 Modulators of tnf-.alpha. signaling
11/22/2001	CA2410091A1 Piperidyindoles as serotonin receptor ligands
11/22/2001	CA2410077A1 Cyclohexyl derivatives and their use as therapeutic agents
11/22/2001	CA2410056A1 Induction of apoptosis and cell growth inhibition by protein 4.33
11/22/2001	CA2409740A1 Novel aryl, alkenyl, and alkynyl 4-dedimethylaminotetracycline desrivatives
11/22/2001	CA2409652A1 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
11/22/2001	CA2409452A1 Methods for enriching for quiescent cells in hematopoietic cell populations
11/22/2001	CA2409445A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001	CA2409437A1 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	CA2409225A1 Tricyclic pyrazole derivatives
11/22/2001	CA2409154A1 Compositions, kits, and methods for identification and modulation of t helper-1 and t helper-2 cells and diseases associated therewith
11/22/2001	CA2409148A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
11/22/2001	CA2409116A1 Substituted thioacetamides
11/22/2001	CA2409108A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
11/22/2001	CA2409077A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
11/22/2001	CA2409035A1 Hydroxamic acid derivatives
11/22/2001	CA2409005A1 Methods for decreasing cell proliferation based on (3r, 4r)-.delta.8-tetrahydrocannabinol-11-oic acids

1 ... 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 ... 1564